ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 0835

Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)

Yan Zhang1, Brittany Ross1, Diana Galvan1, Yanjie Bao1, Daiki Matsuda1, Shaun Grosskurth1, Iago Pinal-Fernandez2, Maria Casal-Dominguez3, Gregor Adams1, Michael Rosenzweig1, Ramin Farzaneh-Far1, Priya Karmali1, Adrian Bot1, Andrew Mammen2 and Haig Aghajanian1, 1Capstan Therapeutics, San Diego, CA, 2NIH, Bethesda, MD, 3NIH, Bathesda, MD

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Cytotoxic Cells, Myositis, Systemic lupus erythematosus (SLE)

Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: T Cell Biology & Targets in Autoimmune & Inflammatory Disease

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID) indications. Despite the success of current CAR T therapies, challenges in cell manufacturing, scalability, utilization of integrating viral vectors, and the need for lymphodepleting chemotherapy, highlight the necessity for an off-the-shelf in vivo CAR technology applicable to broader indications. To that aim, we developed an in vivo anti-CD19 CAR mRNA product delivered by a CD8-targeted lipid nanoparticle (tLNP) (CPTX2309). We tested the applicability of CPTX2309 to engineer T cells with an anti-CD19 CAR and demonstrated the ability for this approach to eradicate target B cells from patients with B cell involved AID.

Methods: To test the potential applicability of CPTX2309 treatment to AID patients, we evaluated the immunophenotype, tLNP-mediated CAR engineering, and functional activity of CAR T cells produced from the peripheral blood of AID patients compared with the peripheral blood of healthy subjects. Samples were obtained from patients with systemic lupus erythematosus (SLE), anti-synthetase syndrome (AS), dermatomyositis (DM), and immune-mediated necrotizing myopathy (IMNM) with various prior treatments, including in some cases immune suppressive or B cell depleting agents.

Results: Phenotypically, the composition of major immune cell populations and expression level of CD19 and CD8 on B cells and CD8+T cells, respectively, was comparable across healthy and diseased subjects, except for the lack of B cells in patients treated with B cell depleting agents. In vitro engineering of non-activated lymphocytes with CPTX2309 resulted in comparable CAR expression by CD8+ T cells from healthy and diseased patients irrespective of prior treatments. In the presence of autologous B cells, tLNP-engineered CAR T cells from AID patients demonstrated upregulation of T cell activation markers, produced cytokines associated with T cell cytotoxicity, and eliminated target cells within 72 hours, comparable to tLNP engineered CAR T cells from healthy subjects.

Conclusion:

CPTX2309 effectively engineered CD8+ T cells from autoimmune disease patients irrespective of prior treatments including immune suppressive agents, to highly express anti-CD19 CAR, and rapidly eradicate primary B cells in vitro.  This may allow for broadening the applicability of CAR technology to B cell involved autoimmune diseases through in vivo engineering of anti-CD19 CAR T cells using a scalable and tunable technology devoid of cells, viral vectors or components, and obviating the need for lymphodepleting conditioning.


Disclosures: Y. Zhang: None; B. Ross: None; D. Galvan: None; Y. Bao: None; D. Matsuda: None; S. Grosskurth: None; I. Pinal-Fernandez: None; M. Casal-Dominguez: None; G. Adams: None; M. Rosenzweig: None; R. Farzaneh-Far: None; P. Karmali: None; A. Bot: None; A. Mammen: None; H. Aghajanian: Pfizer, 6.

To cite this abstract in AMA style:

Zhang Y, Ross B, Galvan D, Bao Y, Matsuda D, Grosskurth S, Pinal-Fernandez I, Casal-Dominguez M, Adams G, Rosenzweig M, Farzaneh-Far R, Karmali P, Bot A, Mammen A, Aghajanian H. Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/effective-engineering-of-cd8-t-cells-from-autoimmune-disease-patients-utilizing-a-cd8-targeted-lipid-nanoparticleencoding-an-anti-cd19-car-mrnacptx2309/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effective-engineering-of-cd8-t-cells-from-autoimmune-disease-patients-utilizing-a-cd8-targeted-lipid-nanoparticleencoding-an-anti-cd19-car-mrnacptx2309/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology